Press Releases | Intrexon http://investors.dna.com/ Exemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research Use http://investors.dna.com/2018-04-16-Exemplar-Genetics-Rare-Neurological-Disease-Model-Cleared-by-FDA-for-Commercial-Research-Use Mon, 16 Apr 2018 07:00:00 -0400 http://investors.dna.com/2018-04-16-Exemplar-Genetics-Rare-Neurological-Disease-Model-Cleared-by-FDA-for-Commercial-Research-Use ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes http://investors.dna.com/2018-03-29-ActoBio-Therapeutics-Greenlighted-by-FDA-to-Commence-a-Phase-Ib-IIa-Trial-with-AG019-for-the-Treatment-of-Early-Onset-Type-1-Diabetes A unique combination approach to oral tolerance made possible by L. lactis therapeutic protein delivery Thu, 29 Mar 2018 09:26:00 -0400 http://investors.dna.com/2018-03-29-ActoBio-Therapeutics-Greenlighted-by-FDA-to-Commence-a-Phase-Ib-IIa-Trial-with-AG019-for-the-Treatment-of-Early-Onset-Type-1-Diabetes Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results http://investors.dna.com/2018-03-01-Intrexon-Announces-Fourth-Quarter-and-Full-Year-2017-Financial-Results - Quarterly GAAP revenues of $77.0 million and net loss attributable to Intrexon of $27.3 million including non-cash charges of $41.5 million - Thu, 01 Mar 2018 16:05:00 -0500 http://investors.dna.com/2018-03-01-Intrexon-Announces-Fourth-Quarter-and-Full-Year-2017-Financial-Results Intrexon to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1st http://investors.dna.com/2018-02-22-Intrexon-to-Announce-Fourth-Quarter-and-Full-Year-2017-Financial-Results-on-March-1st Thu, 22 Feb 2018 08:00:00 -0500 http://investors.dna.com/2018-02-22-Intrexon-to-Announce-Fourth-Quarter-and-Full-Year-2017-Financial-Results-on-March-1st Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters http://investors.dna.com/2018-01-19-Intrexon-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Exercise-of-Option-by-Underwriters Fri, 19 Jan 2018 10:41:00 -0500 http://investors.dna.com/2018-01-19-Intrexon-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Exercise-of-Option-by-Underwriters Intrexon Prices Public Offering of Common Stock http://investors.dna.com/2018-01-17-Intrexon-Prices-Public-Offering-of-Common-Stock Wed, 17 Jan 2018 09:16:00 -0500 http://investors.dna.com/2018-01-17-Intrexon-Prices-Public-Offering-of-Common-Stock Intrexon Announces Proposed Public Offering of Common Stock http://investors.dna.com/2018-01-16-Intrexon-Announces-Proposed-Public-Offering-of-Common-Stock Tue, 16 Jan 2018 16:15:00 -0500 http://investors.dna.com/2018-01-16-Intrexon-Announces-Proposed-Public-Offering-of-Common-Stock Intrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8 http://investors.dna.com/2018-01-04-Intrexons-ActoBio-Therapeutics-to-Present-at-Biotech-Showcase-2018-on-January-8 Thu, 04 Jan 2018 08:35:00 -0500 http://investors.dna.com/2018-01-04-Intrexons-ActoBio-Therapeutics-to-Present-at-Biotech-Showcase-2018-on-January-8 Intrexon to Present at the 36th Annual J.P. Morgan Healthcare Conference http://investors.dna.com/2018-01-04-Intrexon-to-Present-at-the-36th-Annual-J-P-Morgan-Healthcare-Conference Thu, 04 Jan 2018 08:30:00 -0500 http://investors.dna.com/2018-01-04-Intrexon-to-Present-at-the-36th-Annual-J-P-Morgan-Healthcare-Conference Intrexon Corporation Annual CEO Letter http://investors.dna.com/2018-01-02-Intrexon-Corporation-Annual-CEO-Letter Tue, 02 Jan 2018 08:00:00 -0500 http://investors.dna.com/2018-01-02-Intrexon-Corporation-Annual-CEO-Letter Intrexon Announces Key Management Appointments http://investors.dna.com/2017-11-27-Intrexon-Announces-Key-Management-Appointments Mon, 27 Nov 2017 08:00:00 -0500 http://investors.dna.com/2017-11-27-Intrexon-Announces-Key-Management-Appointments Intrexon to Present at the Stifel 2017 Healthcare Conference http://investors.dna.com/2017-11-10-Intrexon-to-Present-at-the-Stifel-2017-Healthcare-Conference Fri, 10 Nov 2017 08:00:00 -0500 http://investors.dna.com/2017-11-10-Intrexon-to-Present-at-the-Stifel-2017-Healthcare-Conference Intrexon Announces Third Quarter 2017 Financial Results http://investors.dna.com/2017-11-09-Intrexon-Announces-Third-Quarter-2017-Financial-Results - Quarterly GAAP revenues of $46.0 million and net loss attributable to Intrexon of $39.7 million including non-cash charges of $24.0 million - Thu, 09 Nov 2017 16:05:00 -0500 http://investors.dna.com/2017-11-09-Intrexon-Announces-Third-Quarter-2017-Financial-Results Intrexon to Announce Third Quarter 2017 Financial Results on November 9th http://investors.dna.com/2017-11-01-Intrexon-to-Announce-Third-Quarter-2017-Financial-Results-on-November-9th Wed, 01 Nov 2017 08:00:00 -0400 http://investors.dna.com/2017-11-01-Intrexon-to-Announce-Third-Quarter-2017-Financial-Results-on-November-9th Intrexon and Arch Pharmalabs Collaborate on Fermentative Production of an API to Replace Existing Process Sourced from Animals http://investors.dna.com/2017-10-23-Intrexon-and-Arch-Pharmalabs-Collaborate-on-Fermentative-Production-of-an-API-to-Replace-Existing-Process-Sourced-from-Animals Mon, 23 Oct 2017 08:00:00 -0400 http://investors.dna.com/2017-10-23-Intrexon-and-Arch-Pharmalabs-Collaborate-on-Fermentative-Production-of-an-API-to-Replace-Existing-Process-Sourced-from-Animals Intrexon CEO to Participate in World Food Prize Leadership Panel on Global Hunger http://investors.dna.com/2017-10-19-Intrexon-CEO-to-Participate-in-World-Food-Prize-Leadership-Panel-on-Global-Hunger Thu, 19 Oct 2017 08:00:00 -0400 http://investors.dna.com/2017-10-19-Intrexon-CEO-to-Participate-in-World-Food-Prize-Leadership-Panel-on-Global-Hunger Intrexon Corporation Enters into $100 Million Preferred Stock Equity Facility http://investors.dna.com/2017-10-16-Intrexon-Corporation-Enters-into-100-Million-Preferred-Stock-Equity-Facility Mon, 16 Oct 2017 16:13:00 -0400 http://investors.dna.com/2017-10-16-Intrexon-Corporation-Enters-into-100-Million-Preferred-Stock-Equity-Facility Intrexon Crop Protection Achieves Milestone in Development of Pioneering Self-Limiting Fall Armyworm Solution http://investors.dna.com/2017-10-16-Intrexon-Crop-Protection-Achieves-Milestone-in-Development-of-Pioneering-Self-Limiting-Fall-Armyworm-Solution Innovative Precision Biological Solution Targets Destructive Fall Armyworm to Help Farmers Globally to Control This Damaging Pest and Increase Food Production Mon, 16 Oct 2017 08:00:00 -0400 http://investors.dna.com/2017-10-16-Intrexon-Crop-Protection-Achieves-Milestone-in-Development-of-Pioneering-Self-Limiting-Fall-Armyworm-Solution Oxitec do Brasil Receives Prestigious Award for Innovation and Impact http://investors.dna.com/press?item=227 The honour recognises company’s results and contribution to the community Wed, 11 Oct 2017 11:05:00 -0400 http://investors.dna.com/press?item=227 Transfer of Regulatory Jurisdiction for Oxitec’s Self-limiting Friendly™ Aedes in the United States http://investors.dna.com/Transfer-of-Regulatory-Jurisdiction-for-Oxitecs-Self-limiting-Friendly-Aedes-in-the-United-States FDA issues final Guidance for Industry, transferring regulatory authority to EPA Wed, 04 Oct 2017 13:00:00 -0400 http://investors.dna.com/Transfer-of-Regulatory-Jurisdiction-for-Oxitecs-Self-limiting-Friendly-Aedes-in-the-United-States Oxitec to Build State-of-the-Art Mosquito Egg Production Unit http://investors.dna.com/Oxitec-to-Build-State-of-the-Art-Mosquito-Egg-Production-Unit UK Prime Minister Theresa May Announces UK facility with Capacity to Generate One Billion Friendly™ Aedes Mosquito Eggs per Week Tue, 19 Sep 2017 11:00:00 -0400 http://investors.dna.com/Oxitec-to-Build-State-of-the-Art-Mosquito-Egg-Production-Unit Oxitec's Innovative Solution to Tackle Growing Diamondback Moth Pest Issue Begins Field Trials http://investors.dna.com/Oxitecs-Innovative-Solution-to-Tackle-Growing-Diamondback-Moth-Pest-Issue-Begins-Field-Trials Eco-Friendly GE Solution Overcomes Increasing Insecticide Resistance in DBM Helping Farmers to Control Damaging Pest and Increase Food Production Tue, 05 Sep 2017 08:03:00 -0400 http://investors.dna.com/Oxitecs-Innovative-Solution-to-Tackle-Growing-Diamondback-Moth-Pest-Issue-Begins-Field-Trials Intrexon to Participate in Upcoming Investor Conferences http://investors.dna.com/2017-08-31-Intrexon-to-Participate-in-Upcoming-Investor-Conferences Thu, 31 Aug 2017 16:01:00 -0400 http://investors.dna.com/2017-08-31-Intrexon-to-Participate-in-Upcoming-Investor-Conferences Intrexon Announces Second Quarter and First Half 2017 Financial Results http://investors.dna.com/2017-08-09-Intrexon-Announces-Second-Quarter-and-First-Half-2017-Financial-Results - Quarterly GAAP revenues of $54.4 million and net loss attributable to Intrexon of $18.7 million including non-cash charges of $17.4 million - Wed, 09 Aug 2017 16:05:00 -0400 http://investors.dna.com/2017-08-09-Intrexon-Announces-Second-Quarter-and-First-Half-2017-Financial-Results Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th http://investors.dna.com/2017-08-02-Intrexon-to-Announce-Second-Quarter-and-First-Half-2017-Financial-Results-on-August-9th Wed, 02 Aug 2017 08:00:00 -0400 http://investors.dna.com/2017-08-02-Intrexon-to-Announce-Second-Quarter-and-First-Half-2017-Financial-Results-on-August-9th